Low -Dose-bevacizumab and Pemetrexed Versus TPC in Metastatic HER2-negative Breast Cancer Patients
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: low-dose-bevacizumab/pemetrexed|DRUG: Treatment of physician's choice
Sponsor: Chinese Academy of Medical Sciences